Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.31 (
beta-glucuronidase
)
7,680
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
D-penicillamine was introduced to treat neonatal hyperbilirubinaemia in 1973 and to prevent retinopathy of prematurity in 1980. In this study we investigated the renal and liver functions of neonates treated with
DPA
and the in vitro effect of the drug on superoxide anion generation and
beta-glucuronidase
release as well as on phagocytic and intracellular killing activation on human peripheral blood granulocytes. Our data concerning the renal and liver functions before and after 3 to 4 days
DPA
treatment reveal no pathological change during short-term administration in the neonatal period. Furthermore, none of the examined
DPA
concentrations influenced the phagocytic or killing activity of neutrophils.
...
PMID:[D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of phagocytes]. 194 83
